+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment of Multiple Myeloma with High-Dose Chemotherapy and Peripheral Blood Stem Cell Transplantation Followed by Maintenance Therapy with Interferon Alpha or by Sequential Maintenance Therapy with Interferon Alpha and Dexametazone Randomized Trial 4W of the Czech Myeloma Group



Treatment of Multiple Myeloma with High-Dose Chemotherapy and Peripheral Blood Stem Cell Transplantation Followed by Maintenance Therapy with Interferon Alpha or by Sequential Maintenance Therapy with Interferon Alpha and Dexametazone Randomized Trial 4W of the Czech Myeloma Group



Blood 100(11): Abstract No 1564, November 16



High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is superior to conventional therapy in response rates as well as in prolongation of event-free survival (EFS) and overall survival (OS) in multiple myeloma (MM). Optimal maintenance therapy after ASCT is unclear. In order to assess the role of interferon alfa (IFN) and IFN plus dexamethasone (IFN/DEX) as the maintenance therapy after ASCT, 246 previously untreated patients with multiple myeloma (MM) were enrolled to the 4W trial from 1996 to 2002. Patients received primary therapy with four cycles of VAD regimen (vincristine, doxorubicin, dexamethasone) followed by mobilization with cyclophosphamide 5g/m2 and G-CSF 10 mug/kg. A conditioning regimen with melphalan 200mg/m2 was used for first and second transplantation. The later was indicated only in patients who did not achieve a good remission (>75% reduction of M-component). After transplantation patients were randomized to two arms of maintenance therapy: IFN 3 x 106 units three times weekly s.c. or the same dose of IFN in alternating cycles with dexamethasone 40 mg on days 1-4, 10-13, 20-23. Data of 151 randomized patients to 31st August 2001 were evaluated in this analysis. One month after transplantation 6 % of patients achieved complete remission (M-component 0% and negative immunofixation), 58 % remission (<75 % reduction of starting level of M-component), 24 % partial remission (<50 % reduction of M-component). Transplant related mortality at day +100 was 2.35 %. All 151 randomized patients received the maintenance therapy, 77 patients in the IFN arm and 74 patients in the IFN/DEX arm. Median of EFS for all 151 patients was 36 months and median of OS was not yet achieved. In analysis, the OS and EFS curves have shown no significant differences between the IFN and IFN/DEX groups (p = 0.593 for EFS; p = 0.316 for OS). Data from more than 180 randomized patients (interim analysis to 31st August 2002) will be available for comparison of the two types of maintenance therapy after autologous transplantation.

(PDF emailed within 1 workday: $29.90)

Accession: 035980538

Download citation: RISBibTeXText


Related references

Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group. Vnitrni Lekarstvi 47 Suppl 1: 40-47, 2001

Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group. Vnitrni Lekarstvi 44(7): 400-408, 1998

High dose melphalan without autologous stem cell transplantation and maintenance therapy with alpha-interferon in previously non treated multiple myeloma. British Journal of Haematology 87(SUPPL 1): 220, 1994

Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation 27(5): 511-515, 2001

Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. European Journal of Haematology 57(2): 142-148, 1996

13 cis-retinoic acid +dexamethasone +alpha interferon An active combination when used as maintenance therapy following high dose chemotherapy and autologous stem cell transplant in patients with multiple myeloma. Blood 102(11): 384b, November 16, 2003

Pilot study of 13cis-retinoic acid plus dexamethasone plus alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma. Bone Marrow Transplantation 35(10): 979-984, 2005

High-dose therapy of multiple myeloma with autologous hematopoietic stem cell transplantation and subsequent maintenance therapy with interferon alfa versus interferon alfa and dexamethasone--a randomized clinical study "4W". Vnitrni Lekarstvi 43(5): 345, 1997

Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. Annals of Internal Medicine 124(2): 212-222, 1996

Maintenance treatment of multiple myeloma with alpha interferon versus an alternating schedule of alpha interferon and chemotherapy. Greek Myeloma Study Group (GMSG). European Journal of Cancer 27 Suppl 4: S49-S50, 1991

Successful treatment of an HIV-positive multiple myeloma patient with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation and maintenance therapy with lenalidomide. Japanese Journal of Clinical Hematology 54(7): 664-669, 2014

High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma Up-front of rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92(9): 3131-3136, Nov 1, 1998

Interferon alfa as maintenance treatment after autologous peripheral blood stem cell transplantation in high risk multiple myeloma. Bone Marrow Transplantation 0(PROGRAM ABSTR ): 176, 1994

Double high dose chemotherapy with autologous stem cell rescue and alpha interferon maintenance as consolidation in myeloma. British Journal of Haematology 93(SUPPL 2): 298, 1996

A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica 94(9): 1274-1281, 2009